Safety of the new generation recombinant factor concentrates

Expert Opinion on Drug Safety

Volumn 1, Issue 3, 2002, Pages 213-223

  Ragni, Margaret V ^a   Schlesinger, Kimberly W ^a  

^a Hemophilia Center of Western PA   (United States)

Author keywords

cost; haemophilia; immunogenicity; recombinant factor; safety; thrombogenicity

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; F8 PROTEIN, HUMAN; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ECONOMICS; FEMALE; GENETICS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MALE; PATHOPHYSIOLOGY; REVIEW;

FACTOR IX; FACTOR VII; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MALE; RECOMBINANT PROTEINS;

EID: 0042736651     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.1.3.213     Document Type: Review

References (79)

1. ROSNER F: Hemophilia in the Talmud and rabbinic writings. Ann. Intern. Med. (1969) 70(4):833-837.
2. MCKUSICK VA: The royal hemophilia. Sci. Am. (1965) 213:88-95.
3. CHORBA TL, HOLMAN RC, STRINE TW et al.: Changes in longevity and causes of death among persons with hemophilia A. Am. J. Hematol. (1994) 45(2):112-121. Analysis of mortality trends in patients with haemophilia A into the early 1990s. (Pubitemid 24092578)
4. EYSTER ME, FRIED MW, DIBISCEGLIE AM, GOEDERT JJ: Increasing hepatitis C RNA levels in hemophiliacs: relationship to human immunodeficiency infection and liver disease. Blood (1994) 84:1010-1013. Description of HIV and HCV among haemophilia patients.
5. KAUFMAN RJ, ANTONARAKIS SE: Structure, biology, and genetics of factor VIII. In: Hematology: Basic Principles and Practice. Hoffman R, Benz EJ, Shattil SJ et al. (Eds), Churchill Livingstone, New York (2000):1850-1868.
6. LEISNER RJ, KHAIR K, HANN IM: The impact of prophylactic treatment on children with severe haemophilia. Br. J. Haematol. (1996) 92:973-978. (Pubitemid 26109507)
7. HOYER LW: Medical progress: hemophilia A. N. Engl. J. Med. (1994) 330(1):38-47.
8. MANNUCCI PM, TUDDENHAM EGD: Medical progress: the hemophilias-from royal genes to gene therapy. N. Engl J. Med. (2001) 344(23):1773-1779. (Pubitemid 32497033)
9. LAKICH D, KAZAZIAN HH, ANTONARAKIS SE, GITSCHIER J: Inversions disrupting the Factor VIII gene as a common cause of severe hemophilia A. Nat. Genet. (1993) 5(3):236-241. (Pubitemid 23330385)
10. NAYLOR J, BRINKE A, HASSOCK S, GREEN PM, GIANNELLI F: Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions. Hum. Mol. Genet. (1993) 2(11):1773-1778. (Pubitemid 23326598)
11. HIGUCHI M, ANTONARAKIS SE, KASCH L et al.: Towards a complete characterization of mild to moderate hemophilia A: detection of the molecular defect in 25 of 29 patients by denaturing gradient gel electrophoresis. Proc. Natl. Acad. Sci. USA (1991) 88(10):8307-8311. (Pubitemid 21915345)
12. GIANNELLI F, CHOO KH, REES DJG, BOYD Y, RIZZA CR, BROWNLEE GG: Gene deletions in patients with haemophilia B and anti-factor IX antibodies. Nature (1983) 303(5913):181-182. (Pubitemid 13081083)
13. LANE S: Haemorrhagic diathesis. Successful transfusion of the blood. Lancet (1840) 1:185.
14. PATEK AJ, TAYLOR FHL: Hemophilia II. Some properties of a substance obtained from normal human plasma effective in accelerating the coagulation of hemophilic blood. J. Clin. Invest. (1937) 16:113.
15. AGGELER PM, WHITE SG, GLENDENNING MB et al.: Plasma thromboplastin component (PTC) deficiency: a new disease resembling hemophilia. Proc. Soc. Exp. Biol. Med. (1952) 79:692.
16. RAGNI MV, RUBEN F, WINKELSTEIN A, SPERO JA, BONTEMPO FA, LEWIS JH: Antibody response to immunofixation in patients with haemophilia with and without evidence of HTLV-III infection. J. Lab. Clin. Med. (1987) 109(5):545-549. (Pubitemid 17074019)
17. RAGNI MV, LUSHER J, KOERPER M, MANCO-JOHNSON M, KRAUSE DS: Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with haemophilia. Haemophilia (2000) 6(2):98-103. (Pubitemid 30166831)
18. LIPTON RA: The economics of Factor VIII inhibitor treatment. Semin. Hematol. (1994) 31(2 Suppl. 4):37-38.
19. EIBL MM, AHMAD R, WOLF HM, LINNAU Y, GOTZ E MANNHALTER JW: A component of Factor VIII preparations which can be separated from Factor VIII activity down regulates human monocyte functions. Blood (1987) 69(4):1153-1160. (Pubitemid 17080939)
20. THORPE R, DILGER P, DAWSON NJ, BARROWCLIFFE TW: Inhibition of interleukin-2 secretion by Factor VIII concentrates: a possible cause of immunosuppression in haemophiliacs. Br. J. Haematol. (1989) 71(3):387-391. (Pubitemid 19086652)
21. CHOO KH, GOULD KG, REES DJ, BROWNLEE GG: Molecular cloning of the gene for human anti-haemophiliac Factor IX. Nature (1982) 299(5879):178-180. (Pubitemid 12056800)
22. VEHAR GA, KEYT B, EATON D et al.: Structure of human Factor VIII. Nature (1984) 312(5992):337-342. (Pubitemid 15209310)
23. WOOD WI, CAPON DJ, SIMONSEN CC et al.: Expression of active human factor VIII from recombinant DNA clones. Nature (1984) 312(5992):330-337. (Pubitemid 15209309)
24. NovoSeven package insert. NovoNordisk, March 1999.
25. Recombinate package insert. Baxter Health Corp., April 2001.
26. ReFacto package insert. Wyeth/Genetics Institute, March 2000.
27. Kogenate FS package insert. Bayer Corp., June 2000.
28. Benefix package insert. Wyeth/Genetics Institute, January 1999.
29. CERVENOKOVA L, BROWN P, HAMMOND DJ, LEE CA, SAENKO EL: Factor VIII and transmissible spongiform encephalopathy: the case for safety. Haemophilia (2002) 8:63-75. (Pubitemid 35238058)
30. BRUCE ME, MCCONNELL I, WILL RG, IRONSIDE JW: Detection of variant Creutzfeldt-Jakob disease infectivity in extraneuronal tissues. Lancet (2001) 358(9277):208-209. (Pubitemid 32718547)
31. SPIELHAUPTER C, SCHATZL HM: PrPc directly interacts with proteins involved in signaling pathways. J. Biol. Chem. (2001) 276:44604-44612.
32. PRUSINER S: Prions. Proc. Natl. Acad. Sci. USA (1998) 95:13363-13383.
33. ANDERSON RM, DONNELLY CA, FERGUSON NM et al.: Transmission dynamics and epidemiology of BSE in British cattle. Nature (1996) 382(6594):779-788. (Pubitemid 26299555)
34. GAJDUSEK DC: Infectious amyloids: subacute spongiform encephalopathies as transmissible cerebral amyloidosis. In: Fields Virology (3rd edn), Knipe BN, Howley PM (Eds), Lippincott-Raven Publishers, Philadelphia (1996):2862-2870.
35. SPARKES RS, SIMON M, COHN VH et al.: Assignment of the human and mouse prion protein genes to homologous chromosomes. Proc. Natl. Acad. Sci. USA (1986) 83(19):7358-7362. (Pubitemid 16000521)
36. BROWN P: Transmissibile human spongiform encephalopathy (infectious cerebral amyloidosis): Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome and kuru. In: Neurodegenerative Diseases. Calne DB (Ed.), WB Saunders, Philadelphia (1994):839-876.
37. BROWN P: Transmission of spongiform encephalopathy through biological products. Dev. Biol. Stand (1998) 93:73-78.
38. PATTISON J: The emergence of bovine spongiform encephalopathy and related diseases. Emerg. Infect. Dis. (1998) 4:390-394. (Pubitemid 28387414)
39. BROWN P, GIBBS CJ, RODGERSJOHNSON P et al.: Human spongiform encephalopathy. The National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann. Neurol. (1994) 35(5):513-529. (Pubitemid 24153834)
40. EVATT B, AUSTIN H, BARHART E et al.: Surveillance of Creutzfeldt-Jakob disease among persons with hemophilia. Transfusion (1998) 38(9):817-820. (Pubitemid 28421641)
41. HOLMAN RC, KAHN AS, KENT J, STRINE TW, SCHONBERGER LB: Epidemiology of Creutzfeldt-Jakob disease in the United States 1979-90: analysis of national mortality data. Neuroepidemiology (1995) 14(4):174-181.
42. WILSON K, CODE C, RICKETTS M: Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: systemic review of case control studies. Br. Med. J. (2000) 321:17-19. (Pubitemid 30417018)
43. DAVANIPOUR Z, ALTER M, SOBEL E, ASHER D, GAJDUSEK DC: Creutzfeldt-Jakob disease: possible medical risk factors. Neurology (1985) 35(10):1483-1486. (Pubitemid 15242428)
44. CREANGE A, GARY F, CESARO ADLEBIASETTE H et al.: Cretuzfeldt-Jakob disease after liver transplantation. Ann. Neurol. (1995) 38(2):269-272.
45. EVATT B: Creutzfeldt-Jakob disease and haemophilia: assessment of risk. Haemophilia (2000) 6(Suppl. 1):94-99. (Pubitemid 30468299)
46. WILL RG, IRONSIDE JW, ZEIDLER M et al.: A new variant of Cruetzfeldt-Jakob disease in the UK. Lancet (1996) 347(9006):921-925. (Pubitemid 3042911)
47. BRUCE MR, WILL RG, IRONSIDE JW et al.: Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature (1997) 389(6650):498-501. (Pubitemid 27435325)
48. HILL AF, DESBRUSLAIS M, JOINER S et al.: The same prion strain causes vCJD and BSE. Nature (1997) 389(6650):448-450. (Pubitemid 27435311)
49. BROWN KE: Parvovirus B-19. In: Mandell: Principles and Practice of Infectious Diseases (5th edn). Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia (2000):1685-1691.
50. COHEN BJ, BUCKLEY MM: The prevalence of antibody to human parvovirus B19 in England and Wales. J. Med. Microbiol. (1988) 25:151-153. (Pubitemid 18061270)
51. COHEN BJ, FIELD AM, GUDNADOTTIR S et al.: Blood donor screening for parvovirus B19. J. Virol. Methods (1990) 30:233-238.
52. BENJAMIN RJ: Nucleic acid testing: update and applications. Semin. Hematol. (2001) 38(4 Suppl. 9):11-16. (Pubitemid 32983348)
53. AYGOREN-PURSUN E, SCHARRER I: A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant Factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group. Thromb. Haemost. (1997) 78(5):1352-1356. (Pubitemid 27491309)
54. EHRENFORTH S, KREUTZ W, SHARRER I et al.: Incidence of development of Factor VIII and Factor IX inhibitors in haemophiliacs. Lancet (1992) 339(8793):594-598.
55. LUSHER JM: Inhibitor antibodies to factor VIII and factor IX: management. Sem. Thromb. Haemost. (2000) 26(2):179-188. (Pubitemid 30439356)
56. LJUNG RC: Gene mutation and inhibitor formation in patients with hemophilia B. Acta Haematol. (1995) 94(Suppl. 1):49-52.
57. HIGH KA: Factor IX: molecular structure, epitopes, and mutations associated with inhibitor formation. Adv. Exp. Med. Biol. (1995) 386:79-86. (Pubitemid 26079032)
58. GIANNELLI F, CHOO KH, REES DJG, BOYD Y, RIZZA CR, BROWNLEE GG: Gene deletions in patients with haemophilia B and anti-factor IX antibodies. Nature (1983) 303(5913):181-182. (Pubitemid 13081083)
59. TOOLE JJ, PITMAN DD, ORR EC, MURTHA P, WASLEY LC, KAUFMAN RJ: A large region (approximately equal to 95 kDA) of human Factor VIII is dispensible for in vitro procoagulant activity. Proc. Natl. Acad. Sci. USA (1986) 83(16):5939-5942. (Pubitemid 16000629)
60. COURTER SG, BEDROSIAN CL: Clinical evaluation of B-domain deleted recombinant Factor VIII in previously untreated patients. Sem. Hematol. (2001) 38(2 Suppl. 4):52-59. (Pubitemid 32618681)
61. ROTH DA, KESSLER CM, PASI KJ, RUP B, COURTER SG, TUBRIDY KL: Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood (2001) 98(13):3600-3606.
62. WARRIER I, LUSHER JM: Development of anaphylactic shock in haemophilia B patients with inhibitors. Blood Coag. Fibrinolysis (1998) 9(Suppl. 1):S125-S128. (Pubitemid 28511580)
63. SAWAMOTO Y, MIDORI S, MASAKUNI Y et al.: Measurement of anti-factor IX subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates. Thromb. Res. (1996) 83(4):279-286. (Pubitemid 26284125)
64. DIOUN AF, EWENSTEIN BM, GEHA RS, SCHNEIDER LC: IgE-mediated allergy and sensitization to Factor IX in hemophilia B. J. Allergy Clin. Immunol. (1998) 102(1):113-117. (Pubitemid 28345791)
65. THORLAND EC, DROST JB, LUSHER JM et al.: Anaphylactic response to factor IX replacement therapy in hemophilia B patients: complete gene deletions confer the highest risk. Haemophilia (1999) 5(2):101-105. (Pubitemid 29182528)
66. EWING NP, SANDERS NL, DIETRICH SL, KASPER CK: Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA (1988) 259(1):65-68.
67. UNUVAR A, WARRIER I, LUSHER JM: Immune tolerance induction in the treatment of pediatric hemophilia A patients with Factor VIII inhibitors. Haemophilia (2000) 6(3):150-157. (Pubitemid 30312467)
68. DIMICHELE DM, KRONER BL: The North American Immune Tolerance Registry: practices, outcomes and outcome predictors. Thromb. Haemost. (2002) 87:52-57. (Pubitemid 34092575)
69. SHAPIRO AD, GILCHRIST GS, HOOTS WK, COOPER HA, GASTINEAU DA: Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb. Haemost. (1998) 80:773-778. (Pubitemid 28521721)
70. LUSHER JM, ROBERTS HR, DAVIGNON G et al.: A randomized, double-blind comparison of two dosage levels of recombinant Factor VIIa in the treatment of joint, muscle and mucocutaneous hemorrhages in persons with hemophilia A and B, with and without inhibitors: rFVIIa Study Group. Haemophilia (1998) 4:790-798. (Pubitemid 28561369)
71. NICOLAISEN EM: Antigenicity of activated recombinant Factor VII followed through nine years of clinical experience. Blood Coag. Fibrinolysis (1998) 95:119-123.
72. KOHLER M, HELLSTERN P, LECHLER E, UBERFUHR P, MULLER-BERGHAUS G: Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb. Haemost. (1998) 80(3):399-402. (Pubitemid 28438732)
73. LUSHER JM: Thrombogenicity associated with factor IX complex concentrates. Sem. Hematol. (1991) 28(Suppl. 6):3-5.
74. FUKUI H, FUJIMARA Y, TAKAHASHI Y, MIKAMI S, YOSHIOKA A: Laboratory evidence of DIC under FEIBA treatment of a hemophiliac patient with intracranial bleeding and high titre factor VIII inhibitor. Thromb. Res. (1982) 22(1-2):177-184. (Pubitemid 11034167)
75. ROBERTS HR: Recombinant factor VIIa (NovoSeven) and the safety of treatment. Semin. Hematol. (2001) 38(4):48-50. (Pubitemid 33130037)
76. ROBINSON KL, SAVOIA H, STREET AM: Thrombotic complications in two patients receving NovoSeven. Haemophilia (2000) 6:343-368.
77. EAGLE C, RENNISON F, MADDOCK K, RICKARD K: Recombinant factor VIIa in a hemophilia A patient with inhibitors. Haemophilia (2000) 6:343-368. Abstract. Case report of local venous thrombus in a haemophilia patient receiving rFVIIa.
78. ALSOLAIMAN MM, CHANG K, ARJOMAND H, COSTACURTA G: Acute left anterior descending artery occlusion in a hemophiliac A patient during recombinant factor VIII infusion: treatment with coronary angioplasty. Catheterization Cardiovasc. Interventions (2000) 50:468-472. (Pubitemid 30603155)
79. MEDICAL AND SCIENTIFIC ADVISORY COMMITTEE: National Hemophilia Foundation. New York, March, 2002.